Dubai (Al-Ittihad) — The Emirates Drug Authority has approved the medication “Wegovy” (semaglutide) from Novo Nordisk as an oral treatment taken once daily for long-term weight management in adults suffering from obesity or weight-related health conditions. “Wegovy” is classified as a GLP-1 receptor agonist, which aids in weight loss and helps maintain results when used alongside a low-calorie diet and increased physical activity. This step is considered a significant achievement in providing new solutions to improve health outcomes and reduce cardiovascular risks.
Benefits of “Wegovy” in Weight Management
“Wegovy” effectively contributes to weight reduction in adults with obesity through its mechanism that supports feelings of fullness. Clinical data has demonstrated the treatment’s ability to reduce the risk of major cardiovascular events, including cardiovascular death, heart attacks, and strokes. This treatment, in turn, enhances heart health among patients who are more susceptible to cardiovascular issues.
The UAE’s Commitment to Embracing Therapeutic Innovations
Dr. Fatima Al Kaabi, Director General of the Emirates Drug Authority, confirmed that the approval of “Wegovy” reflects the authority’s commitment to developing the pharmaceutical system. She emphasized the need to adopt a proactive approach in addressing the challenges of obesity, which is a major factor leading to many chronic diseases. She also highlighted the importance of evaluating and approving treatments in line with established scientific standards.
The Future Vision for Obesity Treatment
Dr. Al Kaabi added: “This step embodies the UAE’s commitment to adopting the latest pharmaceutical innovations, contributing to improved therapeutic outcomes and quality of care.” Her statements underscore the UAE’s strategy to enhance health awareness regarding the importance of early obesity management and reducing its complications.
Partnership with Novo Nordisk
Venkatesh Kalyan, General Manager of Novo Nordisk Gulf, stated: “Collaboration with the Emirates Drug Authority reflects a shared commitment to providing innovative and reliable therapeutic solutions.” He explained that “semaglutide” is known for its excellent safety record and the trust it has garnered within the medical community, as the daily oral formulation offers ease of use, thereby enhancing patient adherence to treatment.